Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
25 drugs in development
By Therapeutic Area
top 3
R&D Momentum
87/100
Pipeline Velocity
57/100
Trial Completion Rate
80/100
Pipeline Concentration
61/100
Pipeline Freshness
52/100
Strategic Signals
Activity
Last 14 days
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
Muscle Aging Phenotypes in Childhood Cancer Survivors
Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)